In a report released today, David Westenberg from Piper Sandler reiterated a Hold rating on Pacific Biosciences (PACB – Research Report), with a price target of $2.00. The company’s shares ...
Bernstein analyst Eve Burstein maintained a Buy rating on Pacific Biosciences (PACB – Research Report) today and set a price target of $2.00. The company’s shares closed yesterday at $1.32.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback